Resistance to Immunotherapeutic Antibodies in Cancer (eBook)
XIII, 202 Seiten
Springer New York (Verlag)
978-1-4614-7654-2 (ISBN)
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
????The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
Part I. Immunotherapy with monoclonal antibodies (mAbs) against various cancers
1.Introduction and generation of chimeric and humanized mAbs
2. mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment
3. Antibodies directed against different major cancers: Effects when used alone or in combination with drugs
4. Mechanisms of antibodies-mediated responses, in vitro and in vivo
Part II. Development of resistance to mAbs
5. Molecular Pathways
6. Molecular Signatures
7. Identification of resistance targets for intervention
Part III. Agents that can sensitize resistant tumor cells to mAbs
8. Various chemicals that can sensitize resitant tumor cells
9. Other mAbs
10. Proteasome inhibitors
Part IV. Novel mAbs to overcome resistance
11. Divalent mAbs
12. Antibodies coupled to chemical inhibitors
13. Antibodies coupled to cytokines 14. Nanoparticles with mAbs
| Erscheint lt. Verlag | 4.8.2013 |
|---|---|
| Reihe/Serie | Resistance to Targeted Anti-Cancer Therapeutics | Resistance to Targeted Anti-Cancer Therapeutics |
| Zusatzinfo | XIII, 202 p. |
| Verlagsort | New York |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
| Naturwissenschaften ► Biologie | |
| Technik | |
| Schlagworte | antibodies • antibody-drug conjugates • cancer drug resistance • MABS • monoclonal antibody • Rituximab |
| ISBN-10 | 1-4614-7654-2 / 1461476542 |
| ISBN-13 | 978-1-4614-7654-2 / 9781461476542 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 4,5 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
